The IDO Metabolic Trap Hypothesis for the Etiology of ME/CFS

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating noncommunicable disease brandishing an enormous worldwide disease burden with some evidence of inherited genetic risk. Absence of measurable changes in patients’ standard blood work has necessitated ad hoc sympto...

Full description

Bibliographic Details
Main Authors: Alex A. Kashi, Ronald W. Davis, Robert D. Phair
Format: Article
Language:English
Published: MDPI AG 2019-07-01
Series:Diagnostics
Subjects:
Online Access:https://www.mdpi.com/2075-4418/9/3/82
_version_ 1817989366680649728
author Alex A. Kashi
Ronald W. Davis
Robert D. Phair
author_facet Alex A. Kashi
Ronald W. Davis
Robert D. Phair
author_sort Alex A. Kashi
collection DOAJ
description Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating noncommunicable disease brandishing an enormous worldwide disease burden with some evidence of inherited genetic risk. Absence of measurable changes in patients’ standard blood work has necessitated ad hoc symptom-driven therapies and a dearth of mechanistic hypotheses regarding its etiology and possible cure. A new hypothesis, the indolamine-2,3-dioxygenase (IDO) metabolic trap, was developed and formulated as a mathematical model. The historical occurrence of ME/CFS outbreaks is a singular feature of the disease and implies that any predisposing genetic mutation must be common. A database search for common damaging mutations in human enzymes produces 208 hits, including IDO2 with four such mutations. Non-functional IDO2, combined with well-established substrate inhibition of IDO1 and kinetic asymmetry of the large neutral amino acid transporter, LAT1, yielded a mathematical model of tryptophan metabolism that displays both physiological and pathological steady-states. Escape from the pathological one requires an exogenous perturbation. This model also identifies a critical point in cytosolic tryptophan abundance beyond which descent into the pathological steady-state is inevitable. If, however, means can be discovered to return cytosolic tryptophan below the critical point, return to the normal physiological steady-state is assured. Testing this hypothesis for any cell type requires only labelled tryptophan, a means to measure cytosolic tryptophan and kynurenine, and the standard tools of tracer kinetics.
first_indexed 2024-04-14T00:46:05Z
format Article
id doaj.art-5ed06f4781d44c099386f9590c5e3aaa
institution Directory Open Access Journal
issn 2075-4418
language English
last_indexed 2024-04-14T00:46:05Z
publishDate 2019-07-01
publisher MDPI AG
record_format Article
series Diagnostics
spelling doaj.art-5ed06f4781d44c099386f9590c5e3aaa2022-12-22T02:22:00ZengMDPI AGDiagnostics2075-44182019-07-01938210.3390/diagnostics9030082diagnostics9030082The IDO Metabolic Trap Hypothesis for the Etiology of ME/CFSAlex A. Kashi0Ronald W. Davis1Robert D. Phair2Stanford Genome Technology Center, Stanford University, Palo Alto, CA 94304, USAStanford Genome Technology Center, Stanford University, Palo Alto, CA 94304, USAIntegrative Bioinformatics Inc., Mountain View, CA 94041, USAMyalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating noncommunicable disease brandishing an enormous worldwide disease burden with some evidence of inherited genetic risk. Absence of measurable changes in patients’ standard blood work has necessitated ad hoc symptom-driven therapies and a dearth of mechanistic hypotheses regarding its etiology and possible cure. A new hypothesis, the indolamine-2,3-dioxygenase (IDO) metabolic trap, was developed and formulated as a mathematical model. The historical occurrence of ME/CFS outbreaks is a singular feature of the disease and implies that any predisposing genetic mutation must be common. A database search for common damaging mutations in human enzymes produces 208 hits, including IDO2 with four such mutations. Non-functional IDO2, combined with well-established substrate inhibition of IDO1 and kinetic asymmetry of the large neutral amino acid transporter, LAT1, yielded a mathematical model of tryptophan metabolism that displays both physiological and pathological steady-states. Escape from the pathological one requires an exogenous perturbation. This model also identifies a critical point in cytosolic tryptophan abundance beyond which descent into the pathological steady-state is inevitable. If, however, means can be discovered to return cytosolic tryptophan below the critical point, return to the normal physiological steady-state is assured. Testing this hypothesis for any cell type requires only labelled tryptophan, a means to measure cytosolic tryptophan and kynurenine, and the standard tools of tracer kinetics.https://www.mdpi.com/2075-4418/9/3/82tryptophan metabolismindoleamine-2,3-dioxygenasebistabilitykynurenine pathwaysubstrate inhibitionmyalgic encephalomyelitischronic fatigue syndromemathematical modelcritical point
spellingShingle Alex A. Kashi
Ronald W. Davis
Robert D. Phair
The IDO Metabolic Trap Hypothesis for the Etiology of ME/CFS
Diagnostics
tryptophan metabolism
indoleamine-2,3-dioxygenase
bistability
kynurenine pathway
substrate inhibition
myalgic encephalomyelitis
chronic fatigue syndrome
mathematical model
critical point
title The IDO Metabolic Trap Hypothesis for the Etiology of ME/CFS
title_full The IDO Metabolic Trap Hypothesis for the Etiology of ME/CFS
title_fullStr The IDO Metabolic Trap Hypothesis for the Etiology of ME/CFS
title_full_unstemmed The IDO Metabolic Trap Hypothesis for the Etiology of ME/CFS
title_short The IDO Metabolic Trap Hypothesis for the Etiology of ME/CFS
title_sort ido metabolic trap hypothesis for the etiology of me cfs
topic tryptophan metabolism
indoleamine-2,3-dioxygenase
bistability
kynurenine pathway
substrate inhibition
myalgic encephalomyelitis
chronic fatigue syndrome
mathematical model
critical point
url https://www.mdpi.com/2075-4418/9/3/82
work_keys_str_mv AT alexakashi theidometabolictraphypothesisfortheetiologyofmecfs
AT ronaldwdavis theidometabolictraphypothesisfortheetiologyofmecfs
AT robertdphair theidometabolictraphypothesisfortheetiologyofmecfs
AT alexakashi idometabolictraphypothesisfortheetiologyofmecfs
AT ronaldwdavis idometabolictraphypothesisfortheetiologyofmecfs
AT robertdphair idometabolictraphypothesisfortheetiologyofmecfs